Drug profile · INN
treprostinil
TREPROSTINIL SCIPHARM SÀRL
- US status
- approved
- Patents linked
- 8
- News articles
- 0
Quick answer
treprostinil (TREPROSTINIL SCIPHARM SÀRL) is an FDA-listed pharmaceutical active ingredient. Associated with United Therapeutics Europe Ltd. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Related patents
Search patents →-
US 12357599
Prodrugs of treprostinil
granted -
US 12173021
Treprostinil prodrugs
granted -
US 12168071
Treprostinil derivatives and their use in pharmaceutical compositions
granted -
US 11826328
Stable treprostinil prodrugs
granted -
US 11723887
Process to prepare treprostinil, the active ingredient in Remodulin®
granted -
US 11672775
Treprostinil prodrugs
granted -
US 11634443
Treprostinil prodrugs
granted -
US 11571444
Enhancement of MSC immunomodulatory properties by treprostinil
granted
Frequently asked questions
What is treprostinil?
treprostinil (TREPROSTINIL SCIPHARM SÀRL) is an FDA-listed pharmaceutical active ingredient. Associated with United Therapeutics Europe Ltd. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for treprostinil?
TREPROSTINIL SCIPHARM SÀRL is a marketed brand name for treprostinil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of treprostinil?
treprostinil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.